Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Dakota Gold Corp. reported a net loss of $25.23 million for the nine months ended September 30, 2026, compared to $20.70 million in the prior year period. The company significantly strengthened its liquidity position, ending the period with $92.15 million in cash and cash equivalents following successful common stock offerings and warrant exercises.
The Grayscale Hyperliquid Staking ETF commenced operations on June 3, 2026, and held 2,219,189.85 HYPE tokens valued at $196.9 million as of September 30, 2026. The Trust recognizes staking rewards as revenue on a net basis under ASC 606 and distributed $368,736 in cash to shareholders from these rewards during the quarter.
For the quarter ended September 30, 2026, Gladstone Land reported total operating revenues of $31.5 million and net income attributable to common stockholders of $6.1 million, a significant improvement from the prior year's quarterly loss. However, for the nine-month period, the company recorded a net loss of $17.4 million, primarily driven by higher impairment charges and property operating expenses.
Capital One Financial Corporation announced that it will present at the KBW Fintech Ecosystem Conference in New York on November 11, 2026. The company will provide a live audio webcast of the presentation via its investor relations website.
Ambow Education Holding Ltd. reported total net revenues of $6.85 million for the nine months ended September 30, 2026, a slight increase from $6.48 million in the prior year. The company experienced a net loss of $0.50 million for the period compared to a net income of $1.27 million in 2025, primarily driven by higher operating expenses and the absence of a prior-year gain on lease settlement.
Anteris Technologies Global Corp. reported a net loss of $78.5 million for the nine months ended September 30, 2026, driven by significant research and development expenses of $62.2 million. The company's financial position improved substantially during the period, with cash and cash equivalents increasing to $232.8 million following the issuance of common stock, resulting in a total stockholders' equity of $226.8 million.
Co-Diagnostics, Inc. reported a net loss of $21.7 million for the nine months ended September 30, 2026, compared to a $21.2 million loss in the prior year. Total revenue increased to $594,966 from $358,567, while cash and cash equivalents significantly decreased to $714,803 from $11.9 million at the start of the year.
Northern Trust $2B Debt Financing with BofA Securities, Inc.
Northern Trust Corporation completed a public offering of $2.0 billion in senior notes, consisting of $1.0 billion of 5.300% Senior Notes due 2031 and $1.0 billion of 5.700% Senior Notes due 2036. The notes are unsecured senior obligations and were issued under a shelf registration statement to provide the company with long-term debt financing.
CoreWeave reported record third quarter 2026 revenue of $3.66 billion, a significant increase from $1.37 billion in the prior year, driven by massive demand for AI infrastructure. Despite the revenue growth, the company reported a net loss of $709 million due to high interest expenses and rapid scaling costs. Management highlighted a revenue backlog of $132.5 billion and plans to receive $9 billion in customer prepayments over the next three months.
Term
Q3 2026
“This was a breakout quarter for CoreWeave, with revenue increasing by more than $1 billion sequentially and adjusted operating margins reaching double digits a quarter ahead of plan.”
Michael Intrator, co-founder, chairman and chief executive officer of CoreWeave
“Our growth is supported by multiple sources of funding, including financing backed by customer contracts, operating cash flow, and approximately $9 billion in customer prepayments and deposits expected in the next three months alone.”
Michael Intrator, co-founder, chairman and chief executive officer of CoreWeave
Fortitude Gold Corp reported a net loss of $4.4 million for the nine months ended September 30, 2026, compared to a net income of $2.3 million in the prior year, primarily driven by a significant increase in exploration and reclamation expenses. Despite the loss, the company strengthened its cash position to $8.5 million through a $17.2 million stock issuance and $5.5 million in funding from noncontrolling interests.
Freenome reported its first quarterly results as a public company, highlighted by $183.5 million in revenue following the FDA approval of its SimpleScreen CRC blood test. The company achieved GAAP net income of $60.1 million, a significant turnaround from a net loss in the prior year, and ended the quarter with $430 million in cash and marketable securities.
Term
Q3 2026
“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”
ACCESS Newswire Inc. reported a net loss of $1.17 million for the nine months ended September 30, 2026, compared to a net income of $4.87 million in the prior year period, which was bolstered by discontinued operations. Total revenues decreased slightly to $16.46 million from $16.82 million year-over-year, while the company maintained a cash balance of approximately $2.99 million.
Braemar Hotels & Resorts Divestiture to Ashford Inc. for $480M
Braemar Hotels & Resorts has completed its transition to a self-managed REIT by terminating its advisory agreement with Ashford Inc. and its affiliates. In connection with the internalization, the company incurred a $480 million liability for termination payments triggered by previous asset sales, which it is settling through cash payments and the transition of management functions in-house.
Orion180 Insurance Group reported third quarter 2026 financial results, highlighted by a 32% increase in net income to $11.5 million and a 60% growth in managed premiums written to $204 million. The quarter marked the company's first as a public entity following its IPO in September 2026, with managed premiums in-force reaching $678 million.
Term
Q3 2026
“We delivered an excellent quarter across our key metrics, rapidly growing our managed premiums while significantly increasing our profitability on a year-over-year basis. In addition, we achieved a major milestone in our Company’s history by successfully completing our initial public offering. We believe our results reflect the strength, differentiation and scalability of the business model we have built over the past eight years.”
Kenneth Gregg, Chief Executive Officer of Orion180
“We are well-positioned to produce durable growth on both our top and bottom lines, which is driven by our attractive suite of homeowners solutions - including our flagship FLEX product - as well as our proprietary end-to-end MY180 tech platform, which allows us to seamlessly combine best-in-class underwriting, claims management, and real-time analytic capabilities.”
Kenneth Gregg, Chief Executive Officer of Orion180
Lumexa Imaging reported Q3 2026 financial results with revenue growing 5% to $272.0 million and net income of $7.2 million. The company reiterated its full-year revenue guidance while raising its Adjusted EPS outlook to $0.86–$0.90 due to a lower effective tax rate.
Term
Q3 2026
“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
Velo3D reported Q3 2026 revenue of $20.5 million, a 50% year-over-year increase, driven by strong demand in aerospace and defense sectors. The company reported a GAAP net loss of $16.7 million as it invested in scaling its new Livermore Production Campus, Forge 1, which is expected to serve as its primary manufacturing center.
Term
Q3 2026
“We delivered solid third quarter results, with revenue increasing approximately 50% year-over-year to $20.5 million and new bookings reaching $28.9 million, exceeding revenue for the quarter. These results reflect continued customer demand for our metal additive manufacturing technology and the progress we are making in executing our growth strategy.”
Arun Jeldi, Chief Executive Officer of Velo3D
“Looking ahead, Forge 1 is central to Velo3D’s next phase of growth and is expected to significantly expand our production capacity as it becomes fully operational, enabling us to pursue larger production programs and capture opportunities across aerospace, defense, space and energy.”
Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.
Term
Q3 2026
“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”
Gene Mack, President and CEO of Gain Therapeutics
“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”
Castellum COO Andrew Merriman Buys $21.9K of Stock
Andrew Merriman, COO, bought 50,000 shares of Castellum, Inc. at $0.4371 a share, worth $21.9K in total on Nov 10, 2026. Shares held after the trade: 639,927 (+8.5%).
Newton Golf Company closed a $1.2 million third tranche of its ongoing private placement, issuing 967,739 shares of common stock at $1.24 per share. The investors included company director Brett Hoge and three other parties. This brings the total raised under the $5 million private placement facility to approximately $2.47 million across three tranches.
Stereotaxis $24M Debt Financing with certain accredited investors
Stereotaxis entered into a Note Purchase Agreement to issue up to $24.0 million in convertible promissory notes, with an initial $12.0 million closing on November 9, 2026. The notes bear 10% interest, mature in three years, and are convertible into common stock at an initial price of $1.21 per share.
Value
$24M
Counterparty
certain accredited investors
Term
3 years
“Our near-term priority is to drive forward two major business model transformations. The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”
David Fischel, Chairman and CEO
“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US.”
Anterix reported its second quarter fiscal 2027 operational results, highlighting $33.1 million in outstanding contracted proceeds and a $6.1 million gain from broadband license exchanges. The company maintained a debt-free balance sheet with $107.5 million in cash and noted that the iPhone 18 Pro is now compatible with its 900 MHz private LTE spectrum.
Rigetti Computing reported Q3 2026 financial results, highlighted by $1.4 million in quarterly revenue and a strong cash position of $497.1 million. The company achieved a key technical milestone with 99.5% median two-qubit fidelity on its 108-qubit system and signed a $100 million agreement with the U.S. Department of Commerce.
Term
Q3 2026
“Rigetti delivered meaningful progress during the third quarter across system performance, technology development and strategic execution. Our Cepheus-1-108Q system achieved our goal of 99.5% median two-qubit gate fidelity, demonstrating continued performance improvement at the 100-plus-qubit level and further validating our chiplet-based approach to scaling superconducting quantum computers.”
Dr. Subodh Kulkarni, Rigetti CEO
“We also signed a definitive $100 million agreement with the U.S. Department of Commerce. Building on the progress achieved this quarter, our next major system objective is to demonstrate a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028.”
Phunware, Inc. initiated a cost-reduction plan involving a 26% reduction in its full-time workforce and the termination of nine consulting contracts. The company expects to incur $0.4 million in severance costs while achieving approximately $2.0 million in annualized cost savings once the process is completed in December 2026.
Nexentis Technologies Inc. issued 72,000 shares of common stock to consultants on November 9, 2026. The shares were issued as payment for various investor relations and business development services provided to the company. The transaction was conducted as a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
Independence Realty Trust M&A Deal with Centerspace
Stockholders of Independence Realty Trust (IRT) and shareholders of Centerspace have approved the previously announced merger between the two multifamily REITs. Under the terms of the agreement, Centerspace shareholders will receive 3.800 shares of IRT common stock for each share owned. The deal creates a leading multifamily REIT focused on high-growth non-gateway markets in the Sunbelt, Midwest, and Mountain West regions.
Tempest Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders elected two Class II directors and ratified Ernst & Young LLP as the independent auditor. Stockholders also approved two key financing-related proposals under Nasdaq rules, including the potential issuance of shares to Lincoln Park Capital Fund and shares issuable upon the exercise of warrants from a September 2026 private placement.
B&G Foods reported third quarter 2026 financial results, featuring a 4.7% increase in net sales to $459.8 million and 5.0% growth in base business net sales. The company raised its full-year 2026 net sales and Adjusted EBITDA guidance while reporting a net loss of $32.5 million for the quarter.
Term
Q3 2026
“Third quarter and year-to-date results reflect encouraging progress across B&G Foods. We generated base business net sales growth of 5.0% in the third quarter and 1.8% year-to-date, while adjusted EBITDA increased $12.4 million, or 6.6%, year-to-date. We are encouraged by this progress and remain focused on building on it.”
Rob Mills, President and Chief Executive Officer
“As we look ahead, our priorities are clear: deliver on our 2026 commitments; build a stronger operating foundation for 2027 and beyond; accelerate productivity and cost savings; improve cash generation; and reduce leverage. We are taking deliberate actions to strengthen B&G Foods, improve financial flexibility and position our company for sustainable long-term performance.”
Alliance Laundry Holdings Inc. reported a significant increase in net income for the nine months ended September 30, 2026, reaching $190.7 million compared to $81.2 million in the prior year. This growth was driven by higher net revenues of $1.36 billion and a substantial reduction in interest expense, which fell from $121.2 million to $52.3 million year-over-year.
Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.
Term
Q3 2026
“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer
Intrusion Inc. entered into a privately-negotiated exchange agreement with Streeterville Capital, LLC to exchange 90 shares of Series B Preferred Stock for 198,396 shares of common stock. The transaction, valued at $99,000, was conducted as a tax-free exchange under Section 3(a)(9) of the Securities Act. This represents a conversion of one equity class into another to satisfy existing obligations without raising new cash.